Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5434552 | 0.84 | MCHR1 (0.62) | MCHR1MAPT | |
| SCHEMBL5442154 | 0.83 | KDM4E (0.47) | ATMKDM4ELMNASMN1; SMN2MCHR1 | |
| SCHEMBL5439346 | 0.79 | MCHR1 (0.60) | MCHR1 | |
| SCHEMBL6465203 | 0.74 | MCHR1 (0.64) | KDM4ELMNASMN1; SMN2MCHR1MAPT | |
| SCHEMBL6465209 | 0.74 | MCHR1 (0.64) | KDM4ELMNASMN1; SMN2MCHR1MAPT | |
| Hydrochloric Acid SCHEMBL6458677 | 0.73 | MCHR1 (0.63) | KDM4ELMNASMN1; SMN2MCHR1MAPT | |
| Hydrochloric Acid SCHEMBL6458685 | 0.73 | MCHR1 (0.63) | KDM4ELMNASMN1; SMN2MCHR1MAPT | |
| SCHEMBL5427862 | 0.73 | MCHR1 (0.49) | KDM4ELMNASMN1; SMN2MCHR1 | |
| SCHEMBL6463308 | 0.73 | SMN1; SMN2 (0.56) | ATMKDM4ELMNASMN1; SMN2MCHR1 | |
| SCHEMBL6463313 | 0.73 | SMN1; SMN2 (0.56) | ATMKDM4ELMNASMN1; SMN2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185079-A1 | Therapeutic agents I | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185079-A1 | Therapeutic agents I | HTT, GRIN2A, GRIN1 | ATM 4435/4885KDM4E 2659/4885LMNA 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.